APA (7th ed.) Citation

ID, G., GI, G., VL, O., VG, C., VS, I., R, B., . . . DF, L. (2025). Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. Pharmaceuticals (Basel, Switzerland), 18(5), . https://doi.org/10.3390/ph18050681

Chicago Style (17th ed.) Citation

ID, Goje, Goje GI, Ordodi VL, Ciobotaru VG, Ivan VS, Buzaș R, Tunea O, Bojin F, and Lighezan DF. "Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology." Pharmaceuticals (Basel, Switzerland) 18, no. 5 (2025). https://doi.org/10.3390/ph18050681.

MLA (9th ed.) Citation

ID, Goje, et al. "Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology." Pharmaceuticals (Basel, Switzerland), vol. 18, no. 5, 2025, https://doi.org/10.3390/ph18050681.